PMID- 35016171
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220603
IS  - 1423-0224 (Electronic)
IS  - 0302-282X (Linking)
VI  - 81
IP  - 3
DP  - 2022
TI  - Extrastriatal Dopamine D2/3 Receptor Availability in Alcohol Use Disorder and 
      Individuals at High Risk.
PG  - 215-224
LID - 10.1159/000521103 [doi]
AB  - INTRODUCTION: Reduced striatal dopamine D2/3 receptor availability in alcohol use 
      disorder (AUD) has been demonstrated in recent clinical studies and 
      meta-analyses. However, only a limited number of studies investigated 
      extrastriatal D2/3 availability in AUD or in at-risk populations. In line with a 
      dimensional understanding of addiction, extrastriatal dopaminergic 
      neuroadaptations have been suggested to be relevant from a pathobiological 
      perspective. METHODS: We investigated D2/3 receptor availability via 
      18F-fallypride positron emission tomography applying a region of interest (ROI) 
      approach. We selected ROIs for the prefrontal cortex (PFC) and the anterior 
      cingulate cortex (ACC). Our sample included 19 healthy controls (low risk [LR]), 
      19 individuals at high risk (HR) to develop addiction, and 20 recently detoxified 
      AUD patients. RESULTS: We found significantly higher D2/3 receptor availability 
      of HR compared to AUD in the left and right rostral ACC (rACC), as well as in the 
      left ventrolateral PFC (vlPFC). We did not observe a significant difference 
      between AUD and LR. After corrections for multiple comparisons none of the ROIs 
      reached significance throughout the group comparison. The D2/3 receptor 
      availability in the left rACC was inversely correlated with symptom severity 
      assessed with the Alcohol Dependency Scale. DISCUSSION: To our knowledge, the 
      present work is the first study investigating extrastriatal D2/3 receptor 
      availabilities in individuals at HR and patients with AUD. The observation that 
      D2/3 receptor availabilities are highest in HR might suggest that their 
      pathobiology differs from subjects with AUD. Future studies are necessary to 
      clarify the intraindividual course of this biomarker over different disease 
      stages and its possible role as a risk or protective factor.
CI  - (c) 2022 S. Karger AG, Basel.
FAU - Spitta, Gianna
AU  - Spitta G
AD  - Department of Psychiatry and Psychotherapy, Charite Campus Mitte (CCM), Charite 
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Gleich, Tobias
AU  - Gleich T
AD  - Department of Psychiatry and Psychotherapy, Charite Campus Mitte (CCM), Charite 
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Zacharias, Kristin
AU  - Zacharias K
AD  - Department of Psychiatry and Psychotherapy, Charite Campus Mitte (CCM), Charite 
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Butler, Oisin
AU  - Butler O
AD  - Center for Lifespan Psychology, Max Planck Institute for Human Development, 
      Berlin, Germany.
FAU - Buchert, Ralph
AU  - Buchert R
AD  - Department of Diagnostic and Interventional Radiology and Nuclear Medicine, 
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Gallinat, Jurgen
AU  - Gallinat J
AD  - Department of Psychiatry and Psychotherapy, University Medical Center 
      Hamburg-Eppendorf (UKE), Hamburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20220111
PL  - Switzerland
TA  - Neuropsychobiology
JT  - Neuropsychobiology
JID - 7512895
RN  - 0 (Pyrrolidines)
RN  - 0 (Receptors, Dopamine D3)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - *Alcoholism/diagnostic imaging
MH  - Corpus Striatum/metabolism
MH  - Dopamine
MH  - Humans
MH  - Positron-Emission Tomography/methods
MH  - Pyrrolidines
MH  - *Receptors, Dopamine D3
OTO - NOTNLM
OT  - Alcohol use disorder
OT  - D2/3 receptor availability
OT  - Dopamine D2/3 receptor
OT  - Extrastriatal
OT  - High risk
OT  - Positron emission tomography
EDAT- 2022/01/12 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/01/11 20:18
PHST- 2021/07/18 00:00 [received]
PHST- 2021/11/18 00:00 [accepted]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2022/01/11 20:18 [entrez]
AID - 000521103 [pii]
AID - 10.1159/000521103 [doi]
PST - ppublish
SO  - Neuropsychobiology. 2022;81(3):215-224. doi: 10.1159/000521103. Epub 2022 Jan 11.